SWTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SWTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of SpringWorks Therapeutics is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, SpringWorks Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, SpringWorks Therapeutics's Risk Assessment distribution charts can be found below:
* The bar in red indicates where SpringWorks Therapeutics's Risk Assessment falls into.
SpringWorks Therapeutics (NAS:SWTX) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of SpringWorks Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Tai-an Lin | officer: Chief Scientific Officer | C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902 |
Julie Hambleton | director | C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Jeffrey Lawrence Schwartz | director, 10 percent owner | C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116 |
Daniel Pichl | officer: Chief People Officer | C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902 |
James Cassidy | officer: Chief Medical Officer | 368 NOD HILL ROAD, WILTON CT 06897 |
Orbimed Advisors Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carlos Alban | director | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Saqib Islam | director, officer: Chief Executive Officer | ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
L. Mary Smith | officer: See Remarks | C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902 |
Bain Capital Life Sciences Investors, Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Michael F. Burgess | officer: Head of Research & Development | C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142 |
Stephen P Squinto | director, 10 percent owner | C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Bhavesh Ashar | officer: Chief Commercial Officer | C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902 |
Orbimed Capital Gp Vi Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Badreddin Edris | officer: Chief Business Officer | C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902 |
From GuruFocus
By sperokesalga sperokesalga • 05-02-2023
By sperokesalga sperokesalga • 05-25-2023
By sperokesalga sperokesalga • 05-30-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 08-02-2023
By sperokesalga sperokesalga • 04-17-2023
By sperokesalga sperokesalga • 03-01-2023
By Value_Insider Value_Insider • 11-03-2022
By Tiesvg Tiesvg • 12-27-2022
By Stock market mentor Stock market mentor • 01-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.